Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers
| 适应症 | Parkinson, Parkinson Disease, Genetic Predisposition, GBA Gene Mutation |
|---|---|
| 分期 | 不适用 |
| 申办方 | Rutgers, The State University of New Jersey |
| 状态 | 已完成 |
| 受试者人数 | 150 人 |
| 开始日期 | 2017年7月1日 |
| 完成日期 | 2024年6月30日 |
| 结果公布日 | 2026年7月29日 |
摘要
Every year, approximately 9,000 Parkinson disease (PD) patients undergo deep brain stimulator (DBS) placement into the subthalamic nucleus (STN-DBS). Studies suggest that PD patients with mutations in the glucocerebrosidase (GBA) gene are at high risk for cognitive impairment and approximately 10-17% of subjects undergoing DBS carry GBA mutations. There may be an interaction between STN-DBS, which also impairs cognitive function, and GBA, resulting in worsened cognitive function. This project will 1) determine the relationship between GBA mutation status and post-operative STN-DBS cognitive function, 2) broaden genotype-phenotype relationships of GBA mutation carriers and 3) provide scientific knowledge regarding the longitudinal cognitive effects of DBS in GBA mutation carriers through repeated neuropsychological testing.
Mattis Dementia Rating Scale
| GBA Mutation Carriers Without DBS | -0.7 points |
|---|---|
| Non-mutation Carriers Without DBS | -0.4 points |
| GBA Mutation Carriers With DBS | -2.4 points |
| Non-mutation Carriers With DBS | -0.9 points |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given P — Merck Sharp & Dohme LLC
- Evaluation of Advanced Imaging and Visualization for Clinical Deep Brain Stimulation — Duke University
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemot — Merck Sharp & Dohme LLC
- A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advan — Merck Sharp & Dohme LLC
- A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With E — Hoffmann-La Roche
- A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson — NeuroDerm Ltd.